Life Sciences Tools and Services

XTALPI

XTALPI released FY2025 9 Months Earnings on March 25 (BJT), actual revenue HKD 715.94 M, actual EPS HKD 0.0286

XTALPI released FY2025 Q3 earnings on March 25 (BJT), actual revenue HKD 156.08 M, actual EPS HKD 0.0047

XTALPI released FY2025 Q4 earnings on March 25 After-Market (BJT), actual revenue HKD 158.77 M, actual EPS HKD 0.0048

XTALPI released FY2025 Annual Earnings on March 25 After-Market (BJT), Actual Revenue HKD 0 (Forecast HKD 731.7 M), Actual EPS HKD 0 (Forecast HKD -0.061)

JingTai Holdings Reports Profit of 135 Million Yuan in FY 2025

XTALPI to Release FY2025 Earnings on March 25 After-Market (BJT), Forecast Revenue HKD 729.75 M, EPS HKD -0.061

ChiTate Holding Expects Profit of at Least 100 Million Yuan in 2025 and Signs Deal with DoveTree

Crystal Holding Expected to Turn Profitable in 2025

JingTai Holdings Delivers Formula Stability Testing Automation Workstation to BASF

Crystal Therapeutics and Sisram Reach Multi-million Yuan Project Collaboration and Long-term Strategic Partnership

ChiTai Holding Completes HK$2.866 Billion Bond Issuance

ChiTech Holdings and Dongyuan Pharma Sign Strategic Cooperation Agreement on AI+Robotics R&D

Chihang Holdings Issued HKD 2.866 Billion Zero-Coupon Bonds

Chihoi Holdings Signs Subscription Agreement to Issue HKD 2.866 Billion Zero-Coupon Convertible Bonds

Jingtae Holding Builds Complete Drug R&D Loop and Expands AI4S Business with Core Technologies

Chiho Holdings distributes 225,000 shares to directors

Yiou Hosts Future Health Summit to Discuss AI Applications and Investment Strategies in Healthcare

Beijing Boundless Evolution Technology Co., Ltd. Established, Focusing on Artificial Intelligence

ChiTau Holding Develops Two New Ingredients for Hair Growth and Prevention of Hair Loss

Cinda Securities Releases Report Analyzing Crystal Holdings' AI Model Capabilities

FAMEGLOW

HAICHANG HLDG

TJCD

NEW GONOW RV

CH DEMETER FIN

REF HOLDINGS

LUEN THAI

ZHONGSHENJIANYE

HUISHENG INTL

INTELLIMARK W27

Jingtai Holdings (02228.HK) 2024 Annual Performance Conference

02228

600000

XtalPi Holdings Limited’s subsidiary, QuantumPharm, has committed RMB356.1 million to low-risk structured deposits from Shanghai Pudong Development Bank. This investment, made on September 11, 2025, is part of a conservative treasury management strategy aimed at enhancing returns on surplus cash while preserving capital. The structured deposits, which are principal-guaranteed and classified as low risk, offer annualized returns between 0.7% and 2.2% and have terms ranging from 27 to 169 days. This move aligns with Hong Kong listing rules for discloseable transactions, reflecting an active cash management approach.

Tip Ranks

SPD Bank

XtalPi’s QuantumPharm Commits RMB356 Million to Low-Risk SPDB Structured Deposits

XTALPI announced a proposal to adopt a new share plan to further align the long-term interests of the company's directors and employees with the long-term interests of the company, and to incentivize them to continue driving the company's growth and development. However, the adoption of the share plan is subject to approval by the company's shareholders at the upcoming annual general meeting through an ordinary resolution

AASTOCKS

XTALPI suggests adopting a new share plan

XTALPI Limited (stock code: 2228) released its financial report for the period ending December 31, 2025, expecting revenue to reach 800 million yuan in 2025, a year-on-year increase of 201%. Among them, revenue from drug discovery solutions is expected to be 538 million yuan, an increase of 418.9%; revenue from AI for Science smart solutions is expected to be 265 million yuan, an increase of 62.6%. Operating profit is expected to be 55.24 million yuan, a significant improvement compared to a loss of 684 million yuan in the same period last year. The company completed the issuance of zero-coupon convertible bonds worth HKD 2.866 billion on January 28, 2026

雷帝触网

XTALPI expects revenue of 800 million in 2025: operating profit of 55.24 million, just issued HKD 2.9 billion bonds

159837

159849

516930

516500

Hong Kong-listed "AI drug discovery star company" XTALPI has delivered its first report of turning losses into profits since its listing. In 2025, XTALPI achieved revenue of 8

- Crystal Holding, an "AI pharmaceutical star" in Hong Kong, reported a significant turnaround in 2025 with a revenue of 802 million CNY, a 201.2% increase year-on-year, and a net profit of 124 million CNY, reversing a loss of 1.517 billion CNY in 2024.  
- The primary driver of revenue was the core business segment "drug discovery solutions," which generated 538 million CNY—an astonishing 418.9% growth—mainly due to a key collaboration with DoveTree in multiple drug development projects.  
- Crystal Holding also benefitted from other income, totaling 514 million CNY, significantly impacting profitability and easing the burden of prior financial losses.

Wallstreetcn

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC CSI Biotechnology Theme ETF

The Reality and Illusion of "AI Drug Discovery" XTALPI's Turnaround

00883

01810

00700

03858

09926

09992

01024

On March 26th at noon, the three major indices of the Hong Kong stock market collectively adjusted, with the Hang Seng Index falling below the 25,000 mark, and the Hang Seng TECH Index experiencing the largest decline. Sector performance was mixed, with individual stocks in life sciences tools and services showing divergent trends, and Jiaxin International Resources plummeting significantly. Popular stocks like Kuaishou and Pop Mart led the market decline, while Xiaomi Group and CNOOC performed strongly, with overall market trading sentiment remaining cautious

- As of noon on March 26, Hong Kong’s three major indices experienced a collective decline, with cautious trading and weak sentiment noted.  
- The Hang Seng Index dropped by 1.37% to 24,988.04, while the Hang Seng Technology Index fell by 2.15% to 4,817.13, both retreating from their March 25 highs.  
- Notable movements included China National Offshore Oil (up 2.39%) and XiaoMi (up 1.54%), while Kuaishou and Alibaba saw significant declines.

Market Pulse

CNOOC

XIAOMI-W

TENCENT

JIAXIN INTL RES

AKESO

POP MART

KUAISHOU-W

Hang Seng TECH Index

Hang Seng Index

Hong Kong Stock Midday Review | Hang Seng Index falls 2.15% leading the decline, CNOOC and Xiaomi rise against the trend

159102

01672

Hong Kong's biopharmaceutical sector saw significant stock gains amid market volatility, with XuanZhu Biopharma-Brising over 12%, Ascletis Pharmaincreasing by more than 7%, and both Lepu Biopharmaand XtalPi Holdingsclimbing over 6%. Akeso Biopharmaalso saw a rise of 5.5%. This trend indicates a positive outlook for the biopharmaceutical industry in Hong Kong's stock market.

CoinLive

Huaan Hang Seng Biotech ETF

ASCLETIS-B

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

LEPU BIO

ICBCCS SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

XUANZHUBIO-B

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hong Kong Biopharmaceutical Stocks Rise Amid Market Volatility

XTALPI announced its performance for the fiscal year 2025, with revenue of RMB 803 million, an annual increase of 201.2%. It turned a loss into a profit of RMB 124 million, compared to a loss of RMB 1.517 billion in the same period last year; earnings per share were 3 cents. No final dividend will be distributed. During the period, adjusted profit was RMB 258 million, compared to a loss of RMB 457 million in the same period last year

"Performance" XTALPI turned a loss into a profit of 124 million RMB for the whole year

XtalPi has appointed Zhou Feiran as its chief financial officer, effective March 10, 2026. Zhou brings experience from J.P. Morgan, where he served as an executive director in global healthcare investment banking. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

PUBT

XtalPi appoints Zhou Feiran as CFO effective March 10, 2026

XTALPI(02228.HK)